Advertisement

Topics

Latest "Cellix Biosciences" News Stories

20:35 EST 22nd January 2019 | BioPortfolio

Here are the most relevant search results for "Cellix Biosciences" found in our extensive news archives from over 250 global news sources.

More Information about Cellix Biosciences on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Cellix Biosciences for you to read. Along with our medical data and news we also list Cellix Biosciences Clinical Trials, which are updated daily. BioPortfolio also has a large database of Cellix Biosciences Companies for you to search.

Showing "Cellix Biosciences" News Articles 1–25 of 1,300+

Extremely Relevant

Cellix Biosciences Completes Pre-IND Meeting with FDA on CLX-103 for Ulcerative Colitis

Cellix Biosciences Inc. (“Cellix Bio”), a development-stage pharmaceutical company, today announced successful completion of a Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for the development of CLX-103, a novel molecular conjugate of mesalamine for the treatment of mild to moderate ulcerative colitis....


Cellix Bio announces completion of Pre-IND meeting with FDA on novel prodrug of mesalamine for ulcerative colitis

Cellix Biosciences Inc., a development-stage pharmaceutical company, today announced successful completion of a Pre-Investigational New Drug meeting with the U.S. Food and Drug Administration for the development of CLX-103, a novel molecular conjugate of mesalamine for the treatment of mild to moderate ulcerative colitis.

Relevant

Cellix Biosciences Announces Regulatory Pathway Confirmation for CLX-106 in the U.S.

Cellix Biosciences Inc. (“Cellix Bio”), a development-stage pharmaceutical company, today announced confirmation from the U.S. Food and Drug Administration (FDA) that the 505(b)(2) regulatory pathway is appropriate for development of CLX-106 for treatment of relapsing-remitting multiple sclerosis (RRMS). CLX-106 is a novel molecular conjugate designed ...


Logic Biosciences Announces International Award for LBS-101 Program

Logic Biosciences, Inc., a development-stage pharmaceutical company, today announced that its lead product candidate, LBS-101, has been recognized with an Innovation in Oral Care Award from the International Association for Dental Research (IADR). LBS-101 is a long-acting topical formulation of a novel salt of bupivacaine, being developed for oral pain fro...

Illumina to Acquire Pacific Biosciences for Approximately $1.2 Billion

Illumina, Inc. and Pacific Biosciences announced they have signed an agreement for Illumina to acquire Pacific Biosciences at a price of $8.00 per Pacific Biosciences share in an all-cash transaction. This price represents a premium of 71% to Pacific Biosciences’ 30 trading day volume weighted avera...

Strategic partnership forms between Taconic Biosciences and Cyagen Biosciences

A strategic partnership has been formed between Taconic Biosciences and Cyagen Biosciences — both global companies that generate custom genetically engineered rodent models and associated services.

Life Biosciences LLC leads strategic investment in Prana

(Life Biosciences) Prana Biotechnology Ltd (ASX: PBT, NASDAQ: PRAN) ('Prana' or 'the Company') has today announced that it has entered into a securities purchase agreement for a lead investment by Boston based Life Biosciences LLC ('Life Biosciences') to raise up to approximately A$44.5 million (approx. US$31.4 million).

Illumina To Acquire Pacific Biosciences At $8.00/shr

SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN) and Pacific Biosciences (PACB) announced an agreement for Illumina to acquire Pacific Biosciences at a price of $8.00 per Pacific Biosciences share in a...

Tosoh Boosts Biosciences with Semba Buy

Japan’s Tosoh has strengthened and expanded its bioscience business following the acquisition of a 33.3% stake in Semba Biosciences. Financial details were not disclosed. Headquartered in Madison, Wisconsin, USA, Semba Biosciences makes and sells continuous simulated moving bed (SMB) chromatrography equipment and bio-related agents.

Kuros Biosciences Ltd.: Kuros Biosciences appoints Strategic Advisory Board

Kuros Biosciences appoints Strategic Advisory Board Schlieren (Zurich), Switzerland, September 25, 2018 - Kuros Biosciences (SIX: KURN) today announced the formation of its Strategic Advisory Boar...

Kuros Biosciences Ltd.: Kuros Biosciences appoints Pascal Longlade as Chief Medical Officer

Kuros Biosciences appoints Pascal Longlade as Chief Medical Officer Schlieren (Zurich), Switzerland, August 23, 2018 Kuros Biosciences AG (SIX: KURN) announced today the appointment of Pascal Long...

FSD Pharma to acquire Therapix Biosciences

The transaction combines two highly-complementary businesses and creates a medical cannabis industry innovator focused on the research and development of advanced cannabinoid treatments. Therapix Biosciences shareholders will receive The post FSD Pharma to acquire Therapix Biosciences appeared first on Pharma Business review.

Illumina to acquire Pacific Biosciences for $1.2bn

California-based Pacific Biosciences offers sequencing systems to help scientists resolve genetically complex problems The company’s technology is claimed to offer high accuracy, ultra-long reads, uniform coverage, and the The post Illumina to acquire Pacific Biosciences for $1.2bn appeared first on Compelo Medical Devices.

FSD Pharma signs binding LOI to buy Therapix Biosciences

The transaction combines two highly-complementary businesses and creates a medical cannabis industry innovator focused on the research and development of advanced cannabinoid treatments. Therapix Biosciences shareholders will receive The post FSD Pharma signs binding LOI to buy Therapix Biosciences appeared first on Pharma Business review.

#Cannabisstocks: Sproutly (CSE:SPR) Closes Acquisition of Infusion Biosciences Canada and SSM

VANCOUVER, British Columbia - August 1, 2018 (Investorideas.com Newswire) Sproutly Canada, Inc. (CSE:SPR) (FRA:38G) ("Sproutly" or the "Company") is pleased to announce that it has completed the acquisition of all of the issued and outstanding shares of Infusion Biosciences Canada Inc. ("Infusion Biosciences Canada") and SSM Partners Inc. ("SSM")

InterVenn BioSciences gets $9.4M boost

A round of financing has pulled in $9.4 million for glycoproteomic-based assay developer InterVenn BioSciences.  -More- 

Iota Biosciences gets $15M boost

A round of Series A financing has brought in $15 million for Iota Biosciences, which is developing millimeter-wide sensors th -More- 

M&As this week: MabSpace Biosciences, Cambrex, Hetero Labs

MabSpace Biosciences has merged with HJB to create a fully-integrated biotherapeutics company named Transcenta Holding. Transcenta will have more than...Read More... The post M&As this week: MabSpace Biosciences, Cambrex, Hetero Labs appeared first on Drug Development Technology.

MabSpace Biosciences merges with bioprocessing technology firm HJB

Hong Kong-based biotech company MabSpace Biosciences has signed a definitive agreement to merge with bioprocessing technologies provider HJB to form...Read More... The post MabSpace Biosciences merges with bioprocessing technology firm HJB appeared first on Pharmaceutical Technology.

Reveal Biosciences, Science Exchange partner to apply AI to pathology

Reveal Biosciences is a San Diego-based company that’s leading the next generation of quantitative histopathology, combining the latest artificial intelligence (AI) techniques with high-quality histology, immunohistochemistry (IHC) and The post Reveal Biosciences, Science Exchange partner to apply AI to pathology appeared first on Compelo Medical Devices.

BMS, Vedanta Biosciences to evaluate Opdivo-VE800 combo in metastatic cancers

In this connection, the Bristol-Myers Squibb and Vedanta Biosciences, an affiliate of PureTech Health, have entered into a clinical collaboration. Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor, The post BMS, Vedanta Biosciences to evaluate Opdivo-VE800 combo in metastatic cancers appeared first on Pharmaceutical Business review.

Assembly Biosciences completes enrolment in two Phase IIa HBV trials

Assembly Biosciences has completed patient enrolment in two ongoing Phase IIa trials evaluating ABI-H0731 for the treatment of chronic hepatitis...Read More... The post Assembly Biosciences completes enrolment in two Phase IIa HBV trials appeared first on Drug Development Technology.

Xenetic Biosciences Aktie: Was ist hier los?

Xenetic Biosciences arbeitet an innovativen neuen Medikamenten und Behandlungsmethoden, welche unter anderem im Kampf gegen Krebs helfen sollen. An der Börse wird das Unternehmen als Geheimtipp geh...

Roche licenses IPF candidate to Ark Biosciences

Roche’s Genentech Inc. licensed Ark Biosciences Inc. exclusive worldwide development and commercialization rights to its Ph...

ABCT, Connecticut’s Newest Accelerator Program for Biosciences Ventures, Announces 2019 Cohort of Life Science Startups

BRANFORD, Conn. (PRWEB) December 17, 2018 ABCT , the Accelerator for Biosciences in Connecticut, announced today the second cohort of emerging biosciences ventures invited to participate in the annual program. Twelve ventures will participate in the 6.5-month-long program that features busin...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks